Trial Profile
Phase III Safety and Immunogenicity Study of 23-valent Pneumococcal Polysaccharide Vaccine: A Double-blind, Randomized and Controlled Clinical Trial With 23-valent Pneumococcal Polysaccharide Vaccine in Healthy Children, Adults, and Elderly
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs Pneumococcal 23 valent vaccine Sinovac Biotech (Primary)
- Indications Pneumococcal infections
- Focus Registrational; Therapeutic Use
- Sponsors Sinovac Biotech
- 09 Dec 2020 According to a Sinovac Biotech media release, results from this study was published in the Human Vaccines and Immunotherapeutics medical journal.
- 09 Dec 2020 According to a Sinovac Biotech media release, the China National Medical Products Administration (NMPA) has approved and issued a Product license for the Companys 23-Valent Pneumococcal Polysaccharide (PPV) Vaccine to prevent the infection by streptococcus pneumonia in adults and children ages 2 years old and above.
- 12 Oct 2017 According to a Sinovac Biotech media release, the company has filed the NDA for its 23-valent Pneumococcal Polysaccharide Vaccine to the CFDA on 3 August 2017. This vaccine is used to prevent streptococcus pneumoniae (pneumococcus) infections such as pneumonia and septicemia among adults aged 65 or older, adults with serious long-term health problems, smokers, and children older than two years with serious long-term health problems.